These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14 related articles for article (PubMed ID: 39056245)
1. Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin and empagliflozin-induced arterial relaxation. Forrester EA; BenÃtez-Angeles M; Redford KE; Rosenbaum T; Abbott GW; Barrese V; Dora K; Albert AP; Dannesboe J; Salles-Crawley I; Jepps TA; Greenwood IA Cardiovasc Res; 2024 Jul; ():. PubMed ID: 39056245 [TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Rao S Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413 [TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Vivian EM Drugs Context; 2014; 3():212264. PubMed ID: 25598831 [TBL] [Abstract][Full Text] [Related]
4. The Na Koepsell H Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700 [TBL] [Abstract][Full Text] [Related]
6. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes. Minze MG; Will KJ; Terrell BT; Black RL; Irons BK Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245 [TBL] [Abstract][Full Text] [Related]